News in early breast cancer this year was marked by updated U.S. Preventive Services Task Force (USPSTF) screening ...

Novartis looks odds on to extend the indications of its CDK4/6 inhibitor Kisqali into early-stage breast cancer, on the back of data from the phase 3 NATALEE trial reported at the ASCO congress.

Kisqali was approved as a treatment for early breast cancer by the U.S. Food and Drug Administration in September, and it has been approved as a treatment for metastatic breast cancer in 99 ...

"Today, many people diagnosed with HR+/HER2- early breast cancer in Europe lack options beyond endocrine therapy to help reduce their risk of cancer coming back. If approved, Kisqali could nearly ...

Basel: This month, the NCCN Clinical Practice Guidelines in Oncology (NCCN Guidelines) for breast cancer were updated to ...

Novartis posted third-quarter results that beat analysts' estimates and raised its full-year outlook, buoyed by strong sales ...

A small clinical trial shows promising results for patients with triple-negative breast cancer who received an ...

“If approved, Kisqali could provide an effective and ... including those with high-risk node-negative disease.” Breast cancer is the most commonly diagnosed cancer in Europe 7.

where Kisqali added to endocrine therapy (ET) significantly reduced the risk of recurrence by 25% versus ET alone across a broad population of patients with HR+/HER2- early breast cancer 2 People ...